Hem/Onc Roundup: PSMA/PET Imaging in Prostate Cancer, Plus New FDA Approval for MM

This week on DocWire, editors spoke with Dr. Stefano Fanti, from the University of Bologna, Italy, about the critical role of PSMA-PET imaging in prostate cancer. “There’s more and more evidence for the importance of PSMA imaging for staging high risk [prostate cancer] and for many other indications,” said Dr. Fanti.

Dr. Stefano Fanti on the Importance of PSMA-PET Imaging in Prostate Cancer

In other news, the U.S. FDA approved a new indication for subcutaneous daratumumab in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma, the sixth indication for this daratumumab formulation in MM.

FDA Approves New Indication of Subcutaneous Daratumumab for Multiple Myeloma


A new study found that, for adolescents and young adults with cancer, geographic distance from the hospital where they were diagnosed is associated with increased risk of later diagnosis and survival. Patients living >50 miles from the hospital had a 1.2-times higher risk of late-stage diagnosis and 1.3-times higher risk of mortality compared to patients who lived within 12.5 miles of a hospital.

For Young Adults with Cancer, Hospital Distance Is Associated with Stage at Diagnosis


A new study found that alcohol consumption was linked to more than 740,000 new cases of cancer diagnosed in 2020 across the globe, or around four percent of total cases. “We urgently need to raise awareness about the link between alcohol consumption and cancer risk among policy makers and the general public,” said Harriet Rumgay, of the International Agency for Research on Cancer.

Alcohol Consumption Linked to 4% of Global Cancer Incidence in 2020